.svg){kind=small}
Apr-2026
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Farmaceutical Rx (Frx) has shown notable fluctuations in its performance across different categories in Ohio. In the Edible category, the brand's rankings have oscillated significantly, starting at 56th in January 2026, improving to 47th in February, dropping to 59th in March, and then rising again to 49th in April. This movement suggests a volatile market presence, with sales peaking in February at $22,430 before experiencing a dip in March. Although the brand did not make it into the top 30 in this category, the fluctuations indicate potential growth opportunities if they can stabilize their performance.
In the Flower category, Farmaceutical Rx (Frx) also experienced shifts in its ranking within Ohio. Starting at 39th in January, the brand dropped to 56th in February, then climbed back to 44th in March, before slightly declining to 46th in April. Despite these changes, the brand maintained a relatively consistent sales volume, with a notable peak in January at $201,273. The absence of a top 30 ranking suggests that while the brand is competitive, there is room for improvement to enhance its standing in this popular category. These patterns highlight the dynamic nature of the cannabis market in Ohio and suggest strategic areas where Farmaceutical Rx (Frx) could focus its efforts to bolster its market position.
Competitive Landscape
In the competitive landscape of the Flower category in Ohio, Farmaceutical Rx (Frx) has experienced notable fluctuations in its market position from January to April 2026. Initially ranked at 39th in January, Frx saw a significant drop to 56th in February, before recovering to 44th in March and slightly declining to 46th in April. This volatility in rank is mirrored in their sales performance, which peaked in January and showed a downward trend in February, followed by a partial recovery in March and a slight dip in April. In comparison, Treehaus Cannabis maintained a stronger position, consistently ranking higher than Frx, although it also experienced a downward trend from 36th to 45th over the same period. Meanwhile, Kynd Cannabis Company demonstrated resilience, improving its rank from 46th to 44th, with sales showing an upward trajectory in April. Standard Farms experienced a significant drop in rank from 32nd to 48th, indicating potential challenges despite its initial strong sales. These dynamics suggest that while Frx has shown the ability to recover from rank declines, it faces stiff competition from brands like Treehaus and Kynd, which are also navigating their own market challenges.
Notable Products
In April 2026, GMO Minis (5.66g) maintained its position as the top-performing product for Farmaceutical Rx (Frx), with sales reaching $707. Banana Kush (3.5g) emerged as the second best-selling product, marking its debut in the rankings this month. Banana Kush (2.83g) experienced a drop from second place in March to third in April, indicating a slight decline in its sales momentum. Gelato x Mosa (2.83g) and Pineapple Kush (3.5g) rounded out the top five, ranking fourth and fifth respectively, both making their first appearance in the rankings. The overall performance shows a dynamic shift in product preferences with new entries gaining traction among consumers.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
